Exercise and Vascular Parameters in Hemodialysis
4 de abril de 2017 atualizado por: Sameena Iqbal
Aerobic Exercise and Vascular Hemodynamic Parameters Among Prevalent Hemodialysis Population
Arterial calcification is very common in the incident hemodialysis population, ranging 71-83%.Given that cardiovascular disease is a major cause of mortality in the hemodialysis population, medial arterial calcification may contribute through increased risk of sudden death and congestive heart failure.
Applanation tonometry is the method of choice to measure pulse wave velocity and pulse wave analysis.
The primary objective will be to assess the effect of a 16 week exercise program on aortic pulse wave velocity as the vascular parameter and gait speed as the physical functioning parameter.
The secondary objectives will assess the effect of the exercise program on ultrafiltration rates, weight, SBP, DBP, BNP, hsTroponin, serum calcium, phosphate, albumin, glucose, LDL, HDL, TG, glycated hemoglobin, hemoglobin, CRP, micro RNAs (21, 126, 133, 146a, 221/222 and 210) and hospitalizations.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
The investigators propose a pilot project to assess the effect of a 16 week aerobic exercise program on arterial stiffness and cardiovascular risk in the hemodialysis population. The primary objective will be to assess the effect of a 16 week exercise program on aortic pulse wave velocity as the vascular parameter and gait speed as the physical functioning parameter. The secondary objectives will assess the effect of the exercise program on ultrafiltration rates, weight, SBP, DBP, BNP, hsTroponin, serum calcium, phosphate, albumin, glucose, LDL, HDL, TG, glycated hemoglobin, hemoglobin, CRP, micro RNAs (21, 126, 133, 146a, 221/222 and 210) and hospitalizations.
Study Design:
Randomized-controlled study of end stage renal disease patients between the age of 18 and 90 years to assess the effect of exercise on arterial stiffness. Our aim is to have 23 patients in both groups. The study period will be 24 weeks-4 weeks for recruitment, 16 weeks for the intervention and 4 weeks for data collection and analysis. The protocol will be submitted to the MUHC Research Ethics Board.
The following outcomes are of interest:
- change in gait speed before and after the exercise program
- change in pulse wave velocity before and after the exercise program
- change in BNP, blood pressure, dialysis ultrafiltration, hemoglobin, micro RNAs before and after the exercise program
Tipo de estudo
Intervencional
Inscrição (Real)
21
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Quebec
-
Montreal, Quebec, Canadá, H3A 1A1
- Royal Victoria Hospital
-
Montreal, Quebec, Canadá, H3G 1A4
- Montreal General Hospital
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 95 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Male or female, aged 18-95 years
- Able to comply with the study procedures and medication
- Written informed consent given
- On a stable in-center hemodialysis regimen (at least 3 times per week) for ≥ 12 weeks prior to recruitment
- Cardiac evaluation within the year with adequate cardiac function to be able to undergo the exercise program
Exclusion Criteria:
- Participation in any clinical trial using an investigational product or device during the 30 days preceding recruitment
- Any physical or psychological disability that would impact study participation, such as severe cerebrovascular disease (ie. hemiparesis, cerebellar ataxia, etc.) or dementia
- Serum iPTH > 250 pmol/L within 30 days prior to screening visit
- Dysrhythmia or severe cardiac disease: CHF Class III-IV; unstable cardiovascular diagnosis (for example MI, CABG, PTCA, CVA, and TIA) within 90 days prior to recruitment
- Severe peripheral vascular disease
- Severe hyperkalemia (>6.5 mmol/L) consistently for the last 2 weeks
- Current active cancer (excluding basal cell carcinoma of the skin)
- Poorly controlled hypertension (systolic > 180mmHg or diastolic > 100mmHg) within 4 weeks prior to recruitment
- Anticipated live donor kidney transplant or any other planned major surgery over the study duration
- History of poor adherence to hemodialysis or medical regimen
- Any disease or condition, physical or psychological that, in the opinion of the investigator, would compromise the safety of the subject or the likelihood of achieving reliable results or increase the likelihood of the subject being withdrawn
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Aerobic Exercise program
Intervention of aerobic exercise
|
The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs.
The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment.
The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down.
The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks.
Blood pressure and heart continuous monitoring will be carried out during the exercise program.
Exercise log sheets will be filled for each session for the 16 weeks.
|
|
Outro: Control
no aerobic exercise program
|
No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in Gait speed
Prazo: at 24 weeks and 48 weeks
|
The gait speed will be measured with a timer (in seconds) as the subject will be asked to walk a 10 foot or 3 meter course and back as quickly as possible.
Two readings will be taken and the average will be recorded.
|
at 24 weeks and 48 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline Pulse wave velocity (PWV)
Prazo: at 24 weeks and 48 weeks
|
PWV measurements will be performed between the carotid and femoral artery sites, to primarily measure the stiffness of the aorta.
A 3-lead ECG will be used in conjunction with a tonometer to measure the pressure pulse waveform sequentially in the two peripheral artery sites
|
at 24 weeks and 48 weeks
|
|
Change from Baseline Pulse wave analysis
Prazo: at 24 and 48 weeks
|
Wave Reflections and Arterial Stiffness.
Analysis of the systolic part of the central pressure waveform will be performed to evaluate PWV and the LV afterload.
The main indices that were described above (in hemodynamic measurements) will be obtained by aortic PWA.
|
at 24 and 48 weeks
|
|
Change from baseline Rand survey
Prazo: at 24 weeks and 48 weeks
|
RAND 36-item survey will be used to assess physical functioning and fatigue.
This survey has been validated in the Hemodialysis population.
The survey consists of 36 items and takes approximately 5-10 minutes to complete.
|
at 24 weeks and 48 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
change from baseline micro RNA levels
Prazo: at 24 weeks and 48 weeks
|
micro RNAs (21, 126, 133, 146a, 221/222 and 210): blood sample will be taken before initiation of dialysis week of baseline measurements and end of study.
|
at 24 weeks and 48 weeks
|
|
change from baseline Brain Natuiretic Peptide
Prazo: at 24 weeks and 48 weeks
|
Brain Natuiretic Peptide: measure before initiation of dialysis at baseline and at the end of study period.
|
at 24 weeks and 48 weeks
|
|
change from baseline troponin levels
Prazo: at 24 weeks and 48 weeks
|
to assess myocardial injury during dialysis at baseline and at the end of the study
|
at 24 weeks and 48 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Sameena Iqbal, McGill University Health Centre/Research Institute of the McGill University Health Centre
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de fevereiro de 2015
Conclusão Primária (Real)
1 de novembro de 2015
Conclusão do estudo (Real)
1 de fevereiro de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
19 de novembro de 2012
Enviado pela primeira vez que atendeu aos critérios de CQ
29 de abril de 2016
Primeira postagem (Estimativa)
2 de maio de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
6 de abril de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
4 de abril de 2017
Última verificação
1 de abril de 2016
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 12-309-GEN
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .